Vivos Therapeutics Seeks $20 Million IPO

0 Comments

Vivos Therapeutics (VVOS) intends to raise $20 million in an IPO of its common stock, according to an S-1 registration statement.

Highlands Ranch, Colorado-based Vivos was founded to develop customized oral devices designed to help people who suffer from mild to moderate obstructive sleep apnea [OSA].

Management is headed by co-founder, Chairman and CEO R. Kirk Huntsman, who was previously founder of Dental One Partners, a large dental service organization.

Below is a brief overview video of Vivos Therapeutics:

The company’s primary offering is the Vivos System, composed of a nighttime appliance and a daytime/nighttime appliance.

Vivos has received at least $21 million from investors.

The firm sells its systems to dental practitioners via a direct sales force that targets prospects in the U.S. and Canada.

In the future, and with some of the proceeds from the IPO, the firm intends to develop strategic partnerships, connect with key opinion leaders, attend trade shows and use digital advertising platforms to introduce practitioners to the system.

Sales and Marketing expenses as a percentage of total revenue have dropped as revenues have increased.

The Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, dropped 1.4x in the most recent reporting period.

According to a 2019 market research report, the global market for sleep apnea devices is expected to reach a value of $12.6 billion by 2025.

This represents a forecast CAGR of 6.8% from 2019 to 2025.

The main drivers for this expected growth are an increasing prevalence of sleep disordered breathing, growing awareness of the condition and a higher treatment rate in regions such as North America.

Also, therapeutic devices accounted for 65% of the market in 2018 and are expected to grow at a CAGR of

CRB USA Designs New Research and Gene Therapy Center for Amicus Therapeutics

0 Comments

Glass doors and floor-to-ceiling windows stream natural light into the new Amicus Center, creating a positive energy in the space. Photography courtesy of CRB USA. 

In addition to the classic “Philly” moniker and being known as the city of brotherly love, “Cellicon Valley” is emerging as a popular nickname for Philadelphia, Pennsylvania, with many new genetic research firms establishing labs within the metropolis. Amicus Therapeutics, a biotechnology company that specializes in researching medications for rare metabolic diseases, recently opened their Global Research and Gene Therapy Center of Excellence in West Philadelphia’s University City neighborhood. Located near distinguished universities and hospitals, Amicus recruited CRB USA, an architecture, engineering, and construction firm dedicated to creating advanced science and technology facilities, to design a state-of-the-art office and laboratory. 

Informal quiet zones are set up throughout the office to facilitate collaboration. Photography courtesy of CRB USA. 

Encompassing a total of 75,000 square feet, CRB devised an inviting, open space that celebrates the researchers and lab technicians by design. Scientists—often cooped up in artificially lit windowless labs—work surrounded by natural light and views of the Philadelphia skyline on the 13th and 14th floor of an urban high-rise. The royal blue of the Amicus logo is used as a bright color motif throughout the entire space, adding a lively edge via furniture, carpets, and transparent panel dividers.

Organization and transparency form symbiotic relationship throughout the space. Photography courtesy of CRB USA. 

From zones filled with heavy-duty machinery and technology to the areas that include traditional workplace features such as meeting rooms and lounge areas, the CRB designers focused on layering humanity into the design. Safety, being of utmost importance, is achieved by giving scientists freedom to move through the clearly identifiable zones—creating a defined path that’s obstacle free. Because not all workers are involved

Alivio Therapeutics Awarded $3.3 Million from U.S. Department of Defense

0 Comments

Award will support advancement of ALV-304 into the clinic for the potential treatment of inflammatory bowel disease

Alivio Therapeutics, a biotechnology company developing an inflammation-targeting disease immunomodulation platform for the potential treatment of chronic and acute inflammatory disorders, today announced a $3.3 million U.S. Department of Defense (DoD) Technology/Therapeutic Development Award to advance its product candidate, ALV-304, for the treatment of inflammatory bowel disease (IBD). The funds will support Alivio’s preclinical research and development activities to potentially enable the filing of an investigational new drug (IND) application for ALV-304.

Alivio’s inflammation-targeting disease immunomodulation approach involves selectively restoring immune homeostasis at inflamed sites in the body, while having minimal impact on the rest of the body’s immune system. Alivio’s proprietary platform has demonstrated proof-of-concept in ten different preclinical models of inflammation. In multiple preclinical models for the treatment of IBD, ALV-304 showed significant improvements in several efficacy endpoints compared to untreated controls. Furthermore, the inflammation-targeting properties were shown to result in very low systemic blood levels, which has the potential to limit systemic side effects.

“Our novel platform technology has the potential to generate inflammation-targeting therapies for the treatment of many acute and chronic inflammatory diseases using biologics, small molecules or drug combinations in an oral formulation. IBD as an indication is a great pairing of our technology and an important clinical need,” said Brian Leuthner, chief executive officer at Alivio. “ALV-304 could potentially offer a novel therapeutic option to improve the health of patients living with moderate to severe forms of IBD. We are excited by this potential and the DoD award that will support our efforts to advance ALV-304 into the clinic.”

IBD is estimated to affect approximately three million people in the United States, and other autoimmune diseases affect over 20 million people in the United

Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics

0 Comments

Genuity Science’s approach combines high-quality, whole-genome sequence and deep phenotype data resulting in better definition of the underlying disease mechanisms. This approach, when coupled with Ionis’ proprietary antisense technology, has the potential to significantly expedite the drug development process through a more direct translation of targets into therapeutics.

Under terms of the multi-year collaboration, Genuity Science will receive a combination of upfront payments and development milestones, plus product royalties.  

“Ionis’ financial strength and the success of our validated antisense technology have positioned us to invest in new technologies that enhance our R&D capabilities,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “The collaboration with Genuity Science gives us the potential to significantly increase our discovery opportunities and better understand the complexities of human diseases based on genetics.”

“We are excited to collaborate with an innovative company like Ionis,” said Rob Brainin, chief executive officer of Genuity Science. “Combining the scale and depth of our datasets and our analytical expertise with Ionis’ pioneering antisense technology can more rapidly translate information into insights with potential to deliver breakthrough therapies to even more patients who need them.”

Learn more by visiting https://contact.genuitysci.com/ionis.

About Genuity Science
Genuity Science is a data sourcing, analytics and insights organization headquartered in Boston, Massachusetts, USA, with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity Science partners with global biopharma companies to offer deep end-to-end discovery services aimed at catalyzing precision health and improving the quality of life for patients around the world. Services include population-scale, disease-specific data sourcing, high-quality sequencing, robust statistical analysis and software tools for analyzing large datasets and artificial intelligence (AI). The company operates advanced CAP-accredited, CLIA-certified genomics laboratories in Woburn, Massachusetts, USA and in Dublin, Ireland and is deeply committed to data stewardship and data governance across

Pain Therapeutics Market 2020: Business Trends, COVID – 19 Outbreak, Emerging Technologies, Growth Opportunities and Regional Forecast to 2025

0 Comments

The MarketWatch News Department was not involved in the creation of this content.

Sep 28, 2020 (TS Newswire via Comtex) —
KD Market Insights has published a report on global Pain Therapeutics market research report. The report offers valuable market insights drivers which would aid the industry leaders to develop and line up their market strategies supported by reliable and accurate data. According to KD Market Insights report, the global Pain Therapeutics market is expected to grow at a CAGR of XX.X% during the forecast period i.e. 2020-2025. The market was held to USD XX.X Million in 2019 and is projected to reach to a valuation of USD XX.X Million in 2025. The report covers a detailed chapter on market segmentation of Pain Therapeutics market covering market segments By Drug Class, By Indication and By Distribution Channel.

The report offers an exhaustive analysis of the market trends, opportunities, growth areas and industry drivers which would help the stakeholders to devise and align their market strategies according to the current and future market dynamics.

Get sample [email protected] https://www.kdmarketinsights.com/sample/5403

On the basis of By Drug Class, the market is examined across – NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics. The Parking Management Market further studied By Indication across – Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia.

Different By Distribution Channel segment analysed in report are – Hospital Pharmacy, Retail Pharmacy Store, and Online Pharmacy. Each sub-segment covers various aspect of market and delivers market size and year-on-year growth.

This research report studied the Pain Therapeutics market to forecast the revenues and analyze the trends in 5 regions i.e. North America, Europe, Asia Pacific, Latin America and Middle East & Africa. This chapter of the report presents